July 12th 2024
This randomized, placebo-controlled, phase 3 clinical trial showed that a 14-day treatment course of oral zuranolone 50 mg/day in MDD led to significantly greater improvements in depressive symptoms when compared with placebo.
Southern California Psychiatry Conference
September 13-14, 2024
Register Now!
Updates on New and Emerging Therapies to Improve Outcomes for Patients With Major Depressive Disorder
View More
PER® Psychiatry Summit
November 7, 2024
View More
5th Annual International Congress on the Future of Neurology®
View More
2023 Annual Psychiatric Times™ World CME Conference
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Patient, Provider, and Caregiver Connection™: Exploring Unmet Needs In Postpartum Depression – Making the Case for Early Detection and Novel Treatments
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
Real Psychiatry 2025
January 17 - 18, 2025
View More
More Than ‘Blue’ After Birth: Managing Diagnosis and Treatment of Post-Partum Depression
View More
Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans
View More
Expert Perspectives in the Recognition and Management of Postpartum Depression
View More
The psychologists appear to believe that large numbers of untreated mentally ill would get better if their psychologists could prescribe medication for them, thereby making up for a resource-poor and underfunded mental health system. There is no lack of prescribers. Psychiatrists know that the biggest problem for the mentally ill isn't a lack of medication, it is the dearth of supportive services available to augment, among other treatments, the taking of medication. So why are psychologists fleeing the duties they have long been mandated to provide? The answer is simple: Money.
Read More
Coming Soon: The Computer-Assisted Diagnostic Interview
August 1st 1997Computer-Assisted Diagnostic Interview (CADI) uses the computer to assist, enhance and improve Traditional Diagnostic Interview (TDI). CADI was first presented at the APA's annual meeting in 1996. CADI modifies both data collection and data processing. It occupies a place between the less-than-reliable TDI and the reliable but time-consuming structured interview like the Structured Clinical Interview for DSM (SCID).
Read More
Steps to Accurate Diagnosis of Substance Abuse
July 1st 1997Because alcohol- and drug-dependent patients tend to develop high rates of symptoms usually associated with common psychiatric syndromes, practitioners often fail to diagnose substance dependence and instead jump to treat more familiar disorders. The risk that such circumstances will occur is understandable given statistics that two of every three alcohol- or drug-dependent individuals meet the criteria for psychiatric disorders and one of every three such individuals meets the criteria for anxiety or depressive disorders.
Read More
Psychoanalysis and Pharmacotherapy - Incompatible or Synergistic?
June 1st 1997Is the rising use of psychotropic medication to treat anxiety and mood disorders incompatible with the psychoanalytic approach? As a psychopharmacologist and psychoanalyst who frequently provides consultation to analysts regarding medication for their patients, Steven P. Roose, M.D., has studied this question and presented his findings and opinions in various scientific papers, books and meetings.
Read More
EEOC Issues ADA Guidelines for Mentally Disabled
June 1st 1997The guidance answers the most commonly asked questions about how ADA affects persons with psychiatric disabilities, said EEOC chairman Gilbert F. Casellas. "It provides practical instruction to employers and persons with psychiatric disabilities on their respective rights and responsibilities."
Read More
Algorithm Project Takes Shape in Texas
June 1st 1997We believe that TMAP [The Texas Medication Algorithm Project] is the first large-scale use of medication algorithms, Rush said, "certainly in a community mental health setting. A project like this may help to lay the groundwork for improved public mental health treatment here and in other states as well." Medication algorithms, according to the project directors, consist of "a series of treatment steps, each of which is defined in turn by the clinical response of the patient to the preceding step."
Read More
Commentary: Against Biologic Psychiatry
December 1st 1996As a practicing psychiatrist, I have watched with growing dismay and outrage the rise and triumph of the hegemony known as biologic psychiatry. Within the general field of modern psychiatry, biologism now completely dominates the discourse on the causes and treatment of mental illness, and in my view this has been a catastrophe with far-reaching effects on individual patients and the cultural psyche at large. It has occurred to me with forcible irony that psychiatry has quite literally lost its mind, and along with it the minds of the patients they are presumably supposed to care for. Even a cursory glance at any major psychiatric journal is enough to convince me that the field has gone far down the road into a kind of delusion, whose main tenets consist of a particularly pernicious biologic determinism and a pseudo-scientific understanding of human nature and mental illness.
Read More
Female Gender, Mood Disorders Are Historically Related
October 1st 1996Mood disorders and their impact on women and their families was the topic of a half-day conference held at New York City's Algonquin Hotel;, former haunt of the famous-and depressed- writer Dorothy Parker, who made at least one suicide attempt there in the early 1900s.
Read More
The past decade witnessed major strides in our understanding and treatment of affective disorders in adults, children and adolescents. One of the baffling problems in child and adolescent psychiatry was the question of psychiatric illness spanning a lifetime. The existence of depressive disorders in prepubertal children has been generally recognized and acknowledged since the 1960s; however, only in the last decade did evidence become available that supports the notion that depression in different ages represents the same entity, albeit manifesting different clinical symptoms in each developmental period (Cytryn and others 1986).
Read More
Scientists Study Serotonin Markers for Suicide Prevention
September 1st 1995Brain serotonin levels as a predictor of suicide has been the subject of intense research scrutiny over the past several years, with scientists trying to find easily accessible markers so that the neurotransmitter's levels might someday be readily measured in clinical settings.
Read More
Venlafaxine in the Treatment of Depression: Practical Considerations
January 1st 1995Venlafaxine (Effexor) is a novel antidepressant recently released to the American market. Its entry into the antidepressant market has been much heralded. The lay press has described the drug as "Prozac with a punch," and many patients were asking for it long before it was available. As the hoopla settles down, we are learning that venlafaxine is a potentially important drug with both advantages and disadvantages over other available antidepressants, including the selective serotonin reuptake inhibitors (SSRIs).
Read More